查看購物車
  • English
  • Japanese
  • Korean
NGS試劑盒市場－全球及區域分析：依工作流程、定序類型、應用、最終使用者及地區分類－分析與預測，2026-2036年
市場調查報告書
商品編碼
2112051

NGS試劑盒市場－全球及區域分析：依工作流程、定序類型、應用、最終使用者及地區分類－分析與預測，2026-2036年

NGS Kits Market - A Global and Regional Analysis: Focus on Workflow, Sequencing Type, Application, End User, and Regional Analysis - Analysis and Forecast Year, 2026-2036
出版日期: | 出版商: BIS Research | 英文 201 Pages | 商品交期: 1-5個工作天內

價格

全球 NGS 試劑盒市場預計到 2025 年將達到 68.434 億美元，到 2036 年將達到 193.569 億美元，2026 年至 2036 年的複合年成長率為 10.09%。

關鍵市場統計數據
預測期 2026-2036
2026年市場規模 74.7億美元
2036年的預測 193.569億美元
複合年成長率 10.09%

隨著定序在基礎基因組學、轉化研究、精準腫瘤學、罕見疾病研究、生殖醫學、感染疾病監測和生物製藥開發等領域的廣泛應用，市場正在擴大。 NGS試劑盒是可重複使用的耗材，用於樣品製備、靶向序列捕獲富集、叢集生成和定序反應，無論採用短讀長或長讀長定序平台。該市場涵蓋研究產品、已經過核准的體外診斷試劑盒以及臨床檢查室購買的用於內部檢驗的檢查室自建檢測（LDT）流程的商用NGS試劑盒。

需求成長的促進因素包括檢體量增加、定序基礎設施的普及、從單基因檢測到多基因和全基因組分析的轉變，以及對標準化和可重複工作流程的需求。學術機構的核心設施、檢查室進行實驗室自建檢測（LDT）的檢查室、製藥和生物技術公司、公共衛生組織以及人群基因組分析項目都在提高定序的頻率和規模，這直接推動了試劑盒、流動池、晶片、品控品和試劑的持續採購。

市場概覽

全球NGS試劑盒市場包括市售的耗材，這些耗材可將萃取的DNA或RNA轉化為平台相容的文庫，富集特定靶標，根據需要產生叢集，並進行定序反應。目標產品樣品製備盒、標靶富集試劑盒、索引和條碼產品、叢集生成耗材、定序試劑組、流動池、晶片、DNA定序試劑盒和RNA定序盒。

此市場規模以製造商為單位進行衡量，涵蓋了用於調查、轉化研究、經認證的體外診斷（IVD）工作流程以及臨床檢查室內部檢驗的實驗室自建檢測（LDT）工作流程的市售NGS試劑盒。 LDT的收入以及定序設備以外的其他活動、獨立定序服務、獨立生物資訊學、資料解讀和其他耗材均不包含在內。然而，定序基礎設施的完善、臨床檢查室的處理能力、LDT的普及以及檢驗檢測項目的擴展是推動試劑盒持續消費的關鍵需求促進因素。

工作流程設計正朝著高通量、多重、自動化、低起始量和應用特定型方向發展。實驗室對試劑盒的需求日益成長，這些試劑盒需要支援大規模索引集、減少人工操作時間、簡化純化流程、降低反應體積，並能對諸如無細胞DNA、FFPE組織、單細胞、微生物樣本和小體積臨床檢體等具有挑戰性的材料提供穩定的性能。這些需求凸顯了整合化學反應系統和自動化流程的價值。

樣品製備和靶向序列捕獲顯著影響文庫的複雜性、覆蓋均勻性、重疊率、變異檢測靈敏度和整體工作流程時間。定序化學和叢集生成決定了讀取輸出量、準確性、循環柔軟性以及所部署平台的使用率。因此，試劑盒、儀器、樣本類型和下游分析要求之間的相容性是採購的核心標準，尤其是在受監管和高通量環境下。

競爭對手主要關注試劑盒的性能、準確性、樣本處理柔軟性、自動化相容性、價格、地理覆蓋範圍、法規遵循、技術支援和供應可靠性。供應商則透過工作流程整合、更高的多重檢測能力、改進的化學方法、更短的處理時間、廣泛的應用範圍以及檢驗的樣本製備和定序試劑組合來脫穎而出。批次間性能可靠性和供應連續性仍然至關重要，因為供應中斷會延遲研究和檢驗計劃以及以患者為中心的檢測操作。

採購決策也反映了開放式工作流程和平台綁定式工作流程之間的權衡。檢查室在檢驗和易用性比柔軟性更重要時，往往傾向於選擇高度整合的試劑盒；而處理大量樣本的研究中心則可能選擇支援方案最佳化和成本管理的模組化化學系統。隨著定序系統速度的提升和應用範圍的擴大，樣本製備能力可能成為瓶頸。因此，人們越來越關注那些能夠提供液體處理、標準化品管、簡化轉移流程以及即使在反應體積減少的情況下也能保持性能的試劑盒。

對產業的影響

NGS試劑盒將定序平台的進步轉化為可操作的實驗室工作流程。這種影響在基因組研究領域尤其顯著，標準化的樣本製備和定序化學方法使研究人員能夠處理大規模的樣本隊列，比較不同機構的數據，並將研究範圍從靶向panel擴展到EXOME、基因組、轉錄組，甚至多體學。儀器的價值在於其能否持續地將生物樣本轉化為高品質的文庫和定序數據，因此工作流程的效率、可重複性、擴充性和平台相容性至關重要。

在精準腫瘤學領域，NGS試劑盒支援腫瘤譜分析、生物標記發現、液態生物檢體研究、治療方案選擇和臨床試驗分層。在罕見疾病和生殖醫學領域，它們能夠進行全外顯子定序（WES）、全基因組定序（WGS）、攜帶者篩檢以及難以分析的基因組區域的分析。公共衛生和感染疾病實驗室利用定序工作流程進行病原體鑑定和監測，而製藥和生物技術公司則將其應用於標靶發現、轉化研究、安全性評估、生物標記項目和患者篩選。 Illumina, Inc.、Agilent Technologies, Inc.、F. Hoffmann-La Roche Ltd.、Bio-Rad Laboratories, Inc.、QIAGEN NV、Takara Bio Inc.、Oxford Nanopore Technologies plc、Thermo Fisher Scientific Inc.、Danaher Corporation、Pacific Biosciences of Califor, Inc. Corporation、seqWell, Inc.、Promega Corporation 和 Creative Biogene 透過其試劑盒產品、化學方法開發、平台整合、自動化和分銷，構成了這個生態系統。

然而，其具體實施取決於各實驗室的經濟狀況和運作能力。樣本製備流程依然複雜，試劑盒和定序耗材價格昂貴，不同平台和檢體類型的方案可能無法直接通用。臨床應用涉及驗證、品管和監管要求，而科研需求則可能因津貼經費的多寡而波動。對供應鏈、冷鏈物流、專業實驗室技術以及批次間重複性的依賴性都會影響處理能力和可靠性。能夠簡化工作流程並同時保持效能和可靠供應的供應商可以緩解這些限制。

這種產業影響遠不止於單一實驗室。標準化試劑盒有助於多中心聯盟統一實驗方案，確保不同隊列之間的可比性，並縮短從研究到轉化​​和臨床實踐的轉化過程。此外，它們還能基於定序設備的普及率創造永續的收入來源。這種關係鼓勵平台供應商和獨立試劑生產商投資更廣泛的檢測項目、共同檢驗的工作流程、技術培訓以及銷售管道夥伴關係，從而降低新興實驗室採用這些技術的門檻。

目錄

第1章：全球NGS試劑盒市場：產業展望

  • 市場概覽與生態系統
    • 介紹
    • NGS技術的演進
    • NGS試劑盒工作流程
    • 專利分析
    • 供應鏈分析
    • 趨勢：對當前和未來影響的評估
    • 監理情勢
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇

第2章：2024-2036年全球NGS試劑盒市場（依工作流程分類）

  • 樣品製備
    • 概述
    • 市場規模及預測
    • 樣品製備工具包
    • 靶向序列捕獲盒
  • 叢集生成
  • 定序試劑和試劑盒
    • 概述
    • 市場規模及預測
    • DNA定序盒
    • RNA定序盒

第3章：2024-2036年全球NGS試劑盒市場（依定序類型分類）

  • WES 和 WGS
  • 標靶定序
  • 長讀長定定序
  • 其他定序

第4章：2024-2036年全球NGS試劑盒市場（依應用領域分類）

  • 腫瘤學
    • 概述
    • 市場規模及預測
    • 固體癌
    • 骨髓惡性腫瘤
  • 罕見疾病
  • 遺傳性疾病
  • 生殖健康
  • 感染疾病
    • 概述
    • 市場規模及預測
    • 病毒感染疾病
    • 細菌感染疾病
    • 真菌和寄生蟲感染疾病
  • 其他

第5章：2024-2036年全球NGS試劑盒市場（依最終用戶分類）

  • 學術和研究機構
  • 製藥和生物技術公司
  • 臨床和診斷檢測機構
  • 其他最終用戶

第6章：2024-2036年全球NGS試劑盒市場（按地區分類）

  • 區域概況
  • 北美洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
  • 歐洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
  • 亞太地區
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
  • 拉丁美洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
  • 世界其他地區
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測

第7章：競爭標竿分析與公司概況

  • 關鍵策略和趨勢
    • 新產品和服務
    • 併購
    • 合作夥伴關係、聯盟和業務拓展
  • 公司簡介
    • Bio-Rad Laboratories, Inc.
    • MGI Tech Co., Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Agilent Technologies, Inc.
    • QIAGEN NV
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Illumina, Inc.
    • New England Biolabs, Inc.
    • Oxford Nanopore Technologies plc
    • Pacific Biosciences of California, Inc.
    • Revvity, Inc.
    • Twist Bioscience Corporation
    • seqWell, Inc.
    • Takara Bio Inc.

第8章：調查方法

Product Code: BHP1307SB

This report can be delivered within 1 working day.

Introduction of the NGS Kits Market

The global NGS kits market, valued at $6,843.4 million in 2025, is projected to reach $19,356.9 million by 2036, registering a compound annual growth rate (CAGR) of 10.09% during 2026-2036.

KEY MARKET STATISTICS
Forecast Period2026 - 2036
2026 Evaluation$7,400.7 Million
2036 Forecast$19,356.9 Million
CAGR10.09%

The market is expanding as sequencing becomes embedded in basic genomics, translational research, precision oncology, rare-disease investigation, reproductive health, infectious-disease surveillance, and biopharmaceutical development. NGS kits are recurring consumables used in library preparation, target enrichment, cluster generation, and sequencing reactions across short-read and long-read platforms. The market includes research-use-only products, authorized in vitro diagnostic kits, and commercially manufactured NGS kits purchased by clinical laboratories for internally validated laboratory-developed test (LDT) workflows.

Demand is supported by rising sample volumes, broader access to sequencing infrastructure, the transition from single-gene testing to multigene and genome-scale analysis, and the need for standardized, reproducible workflows. Academic core facilities, clinical laboratories, including laboratories performing LDTs, pharmaceutical and biotechnology companies, public-health organizations, and population-genomics programs are increasing the frequency and scale of sequencing, directly supporting repeat purchases of kits, flow cells, cartridges, controls, and reagents.

Market Introduction

The global NGS kits market includes commercially supplied consumable products that convert extracted DNA or RNA into platform-compatible libraries, enrich selected targets, generate clusters where required, and execute sequencing reactions. In-scope products include library preparation kits, target enrichment kits, indexing and barcoding products, cluster-generation consumables, sequencing reagent kits, flow cells, cartridges, DNA sequencing kits, and RNA sequencing kits.

The market is measured at the manufacturer level and includes commercially purchased NGS kits used in research, translational studies, authorized IVD workflows, and internally validated LDT workflows conducted by clinical laboratories. Laboratory testing revenue generated from LDTs is excluded, as are sequencing instruments, standalone sequencing services, standalone bioinformatics, data interpretation, and other non-consumable activities. However, the installed sequencing base, clinical-laboratory capacity, LDT adoption, and expansion of validated test menus act as important demand enablers for recurring kit consumption.

Workflow design is shifting toward higher-throughput, multiplexed, automated, low-input, and application-specific formats. Laboratories increasingly seek kits that support large index sets, reduced hands-on time, simplified cleanup, smaller reaction volumes, and consistent performance across challenging materials such as cell-free DNA, FFPE tissue, single cells, microbial samples, and limited clinical specimens. These requirements increase the value of integrated chemistries and automation-ready protocols.

Library preparation and target enrichment strongly influence library complexity, coverage uniformity, duplicate rates, variant sensitivity, and total workflow time. Sequencing chemistry and cluster generation determine read output, accuracy, cycle flexibility, and utilization of the installed platform. Consequently, compatibility between kits, instruments, sample types, and downstream analytical requirements is a central purchasing criterion, especially in regulated or high-throughput environments.

Competition centers on kit performance, accuracy, sample-input flexibility, automation compatibility, pricing, geographic reach, regulatory readiness, technical support, and supply reliability. Suppliers are differentiating through workflow consolidation, higher multiplexing, improved chemistry, faster turnaround, broader application menus, and validated combinations of preparation and sequencing reagents. Reliable lot-to-lot performance and continuity of supply remain important because interruptions can delay studies, validation schedules, and patient-facing laboratory operations.

Purchasing decisions also reflect the trade-off between open and platform-linked workflows. Laboratories may favor tightly integrated kits when validated performance and ease of use outweigh flexibility, while high-volume research centers may select modular chemistries that support protocol optimization and cost control. As sequencing systems become faster and more accessible, preparation capacity can become the limiting step. This shifts attention toward liquid handling, standardized quality control, reduced transfer steps, and kits that preserve performance when reaction volumes are scaled down.

Industrial Impact

NGS kits translate advances in sequencing platforms into usable laboratory workflows. Their impact is visible in genomics research, where standardized preparation and sequencing chemistry allow investigators to process larger cohorts, compare data across sites, and extend studies from targeted panels to exomes, genomes, transcriptomes, and multi-omics. Workflow efficiency, reproducibility, scalability, and platform compatibility are critical because the value of the instrument depends on consistent conversion of biological samples into high-quality libraries and sequence data.

In precision oncology, NGS kits support tumor profiling, biomarker discovery, liquid-biopsy research, therapy selection, and clinical-trial stratification. In rare disease and reproductive health, they enable WES, WGS, carrier screening, and analysis of difficult genomic regions. Public-health and infectious-disease laboratories use sequencing workflows for pathogen characterization and surveillance, while pharmaceutical and biotechnology companies apply them to target discovery, translational research, safety assessment, biomarker programs, and patient selection. Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., QIAGEN N.V., Takara Bio Inc., Oxford Nanopore Technologies plc, Thermo Fisher Scientific Inc., Danaher Corporation, Pacific Biosciences of California, Inc., MGI Tech Co., Ltd., New England Biolabs, Inc., Twist Bioscience Corporation, seqWell, Inc., Promega Corporation, and Creative Biogene collectively shape this ecosystem through kit portfolios, chemistry development, platform integration, automation, and distribution.

Adoption nevertheless depends on laboratory economics and operating capability. Preparation steps can remain complex, kits and sequencing consumables can be costly, and protocols may not transfer directly across platforms or specimen types. Clinical use introduces validation, quality-control, and regulatory requirements, while research demand can fluctuate with grant funding. Supply-chain dependence, cold-chain logistics, specialized laboratory expertise, and lot-to-lot reproducibility can affect throughput and confidence. Suppliers that simplify workflows while maintaining performance and dependable availability can reduce these constraints.

The industrial effect extends beyond individual laboratories. Standardized kits help multi-site consortia align protocols, support comparability across cohorts, and shorten the transfer of methods from research into translational and clinical settings. They also create a recurring-revenue layer around the installed base of sequencing instruments. This relationship encourages platform vendors and independent reagent companies to invest in broader menus, co-validated workflows, technical education, and channel partnerships that can lower adoption barriers in emerging laboratories.

Market Segmentation:

Segmentation 1: By Workflow

  • Library Preparation
    • Library Preparation Kits
    • Target Enrichment Kits
  • Cluster Generation
  • Sequencing Reagents/Kits
    • DNA Sequencing Kits
    • RNA Sequencing Kits

Library Preparation Segment to Dominate the Global NGS Kits Market (by Workflow)

Library preparation accounted for the largest workflow share in 2025 and is expected to grow at the fastest rate during 2026-2036. Every sequencing project requires reliable conversion of diverse sample types into libraries, creating recurring demand as sequencing volumes rise. Target enrichment, multiplexing, low-input protocols, and automation-ready formats expand the number and complexity of preparation steps addressed by commercial kits. Optimized library construction remains particularly important for cfDNA, FFPE, single-cell, RNA, microbial, and population-scale applications, where input quantity and workflow consistency affect usable reads. Cluster Generation and Sequencing Reagents/Kits remain essential downstream consumables, but library preparation spans a wider range of samples, applications, and platform-specific workflows.

Segmentation 2: By Application

  • Oncology
    • Solid Tumors
    • Hematological Malignancies
  • Rare Diseases
  • Genetic Disorders
  • Reproductive Health
  • Infectious Diseases
    • Viral Infections
    • Bacterial Infections
    • Fungal & Parasitic Infections
  • Others

Oncology Segment to Dominate the Global NGS Kits Market (by Application)

Oncology held the largest application share in 2025, supported by extensive use of NGS in tumor profiling, biomarker discovery, therapy selection, liquid-biopsy research, treatment-response monitoring, and clinical trials. Solid-tumor and hematological-malignancy workflows require targeted panels, exome or genome analysis, RNA sequencing, and increasingly multiomic approaches, generating repeated demand for preparation, enrichment, and sequencing consumables. The rare diseases segment is expected to grow at the fastest rate as WES and WGS are adopted for unresolved diagnostic cases, sequencing costs decline, interpretation improves, and national genomics initiatives broaden access. Genetic disorders, reproductive health, infectious diseases, and other applications further diversify kit requirements by sample type, target breadth, throughput, and turnaround time.

Segmentation 3: By Sequencing Type

  • WES and WGS
  • Targeted Sequencing
  • Long Read Sequencing
  • Other Sequencing

WES and WGS Segment to Dominate the Global NGS Kits Market (by Sequencing Type)

WES and WGS accounted for the largest sequencing-type share in 2025 because they deliver broad genomic information for rare-disease research, population genomics, complex-trait studies, oncology research, and reference-genome development. Large cohorts and repeat sequencing runs sustain demand for scalable library-preparation and sequencing kits. Long read sequencing is expected to grow at the fastest rate as accuracy, throughput, sample-preparation options, and platform availability improve. Its ability to resolve structural variants, repeat expansions, haplotypes, full-length transcripts, and difficult genomic regions is expanding adoption across rare disease, population genomics, infectious disease, and research applications. Targeted sequencing remains important where depth, speed, and focused content are priorities.

The sequencing-type mix influences both kit design and purchasing cadence. WES and WGS workflows emphasize scalable input normalization, indexing capacity, coverage uniformity, and cost per sample, whereas targeted sequencing prioritizes efficient enrichment and deep, consistent coverage. Long-read workflows place greater emphasis on high-molecular-weight DNA handling, length preservation, and chemistries that capture native molecular information. These differing requirements create room for specialized suppliers even as integrated platform portfolios expand.

Segmentation 4: By End User

  • Academic and Research Institutions
  • Pharmaceutical and Biotechnology Companies
  • Clinical and Diagnostic Laboratories
  • Other End Users

Academic and Research Institutions to Dominate the Global NGS Kits Market (by End User)

Academic and research institutions held the largest end-user share in 2025 and are expected to grow at the fastest rate during the forecast period. Genomics funding, shared core facilities, population studies, translational programs, method development, training, and expanding multi-omics research generate broad demand across library preparation, enrichment, DNA sequencing, and RNA sequencing. These institutions also test new platforms and applications before wider adoption. Pharmaceutical and biotechnology companies require kits for discovery, biomarker, translational, and clinical-trial programs, while clinical and diagnostic laboratories prioritize standardized, validated, reproducible workflows for oncology, inherited disease, reproductive health, and infectious-disease testing.

Segmentation 5: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest-of-Latin America
  • Rest-of-the-World

North America to Dominate the Global NGS Kits Market (by Region)

North America accounted for the largest regional share in 2025, supported by substantial genomics funding, a dense base of sequencing infrastructure and core facilities, established clinical-genomics programs, extensive biotechnology and pharmaceutical activity, and the presence of major kit and platform suppliers. The U.S. anchors demand through large research cohorts, oncology programs, rare-disease networks, biopharmaceutical pipelines, and advanced clinical laboratories, while Canada contributes through national and provincial genomics initiatives and academic research.

Asia-Pacific is expected to grow at the fastest rate during 2026-2036 as sequencing capacity expands, national genomics programs attract investment, clinical laboratories develop molecular capabilities, and regional suppliers strengthen local manufacturing and distribution. China, Japan, India, South Korea, and Australia are increasing adoption across population genomics, oncology, inherited disease, reproductive health, agriculture, and infectious-disease surveillance. Broader access to automation-ready and application-specific kits is expected to support recurring consumable demand across the region.

Europe remains an important market through established genomics institutes, biobanks, clinical research networks, and coordinated rare-disease and cancer programs. Latin America and the Rest-of-the-World represent developing opportunities as laboratory infrastructure, training, funding, and distributor coverage improve. Across these regions, adoption is likely to depend on affordable workflow configurations, local technical support, reliable logistics, and kits capable of performing consistently across varied laboratory environments.

Recent Developments in the NGS Kits Market

  • In May 2026, Pacific Biosciences of California, Inc. announced worldwide shipping of SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for the Revio HiFi platform. The consumable update was designed to lower sequencing cost while improving yield consistency and expanding methylation detection for large-scale genomics.
  • In April 2025, Agilent Technologies, Inc. presented an expanded Avida DNA Cancer Panel portfolio comprising three new NGS target-enrichment panels for simultaneous DNA and methylation profiling. The panels were designed for rapid, ultra-sensitive analysis of circulating cell-free DNA and could generate sequencing-ready libraries within a five-hour workflow.
  • In January 2025, Illumina, Inc. announced new NovaSeq X 25B 100-cycle and 200-cycle kits and the availability of Illumina Single-Cell 3' RNA Prep. The updates expanded cycle flexibility and supported high-throughput multiomic and single-cell sequencing workflows across the NovaSeq X platform.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Routine Clinical NGS Integration across Established Diagnostic Pathways Expands Recurring Kit Consumption: Routine clinical integration of NGS into funded diagnostic pathways is expanding recurring demand for library-preparation, enrichment, indexing, control, and sequencing kits. Oncology leads consumption as sequencing supports tumor classification, therapy selection, clinical-trial matching, and resistance assessment. Rare-disease, inherited-disorder, and reproductive-health testing further increases exome, genome, family-indexing, and cell-free DNA workflows. National test directories, regulatory approvals, reimbursement policies, and commissioned laboratory services convert eligible patients into repeatable sequencing runs. Growth will depend on expanded indications, laboratory capacity, and evidence-based adoption. However, centralized procurement, multiplexing, and declining reagent costs may cause overall kit revenue to grow more slowly than clinical sequencing volumes.

Active Public Genomics and Pathogen-Surveillance Programs Sustain Programmatic Consumables Procurement: Active public genomics and pathogen-surveillance programs support recurring procurement of library-preparation kits, indexes, controls, sequencing reagents, flow cells, and rapid-run cartridges. National population cohorts generate large-scale whole-genome, exome, RNA, and long-read sequencing demand, while standing surveillance networks sustain workflows for viral, bacterial, fungal, parasitic, foodborne, and antimicrobial-resistance threats. Demand becomes commercially meaningful when funding produces enrolled participants, collected specimens, operational laboratories, and completed sequencing runs. Procurement may remain uneven because cohort milestones, outbreaks, budget cycles, and specimen logistics influence ordering. Forecasts should therefore measure funded annual public-sector sample throughput rather than headline program budgets, which also cover infrastructure and workforce.

Market Challenges

Fragmented Reimbursement, Regulatory, and Validation Requirements Delay Clinical Adoption and Market Access: Fragmented reimbursement, regulatory, and validation requirements delay clinical adoption by creating separate hurdles between technical performance and routine paid testing. Laboratories may postpone NGS kit procurement when authorization pathways, payer coverage, local validation, and evidence standards differ across jurisdictions. Restrictions involving disease stage, assay status, intended use, specimen type, or prior authorization can reduce eligible samples converted into sequencing runs. Manufacturers also face higher documentation, quality-system, and conformity-assessment costs, particularly for complex or frequently modified assays. Although harmonization may gradually reduce duplication, policy uncertainty and validation burdens are likely to slow market access and concentrate purchasing among large, well-resourced laboratories.

Market Opportunities

Scaling Genome-First Newborn and Population Screening from Pilots into Routine Care: Scaling genome-first newborn and population screening from pilots into routine care could create recurring demand for whole-genome library kits, indexes, sequencing reagents, flow cells, controls, and confirmatory products. Newborn screening offers a defined, annually replenishing population and can use centralized laboratory infrastructure. Broader population programs could support inherited-risk and pharmacogenomic assessment. Commercial adoption, however, depends on demonstrated clinical utility, actionable findings, consent, turnaround, data governance, treatment pathways, and sustainable funding or reimbursement. Implementation is expected to progress gradually from evidence-generating studies to commissioned programs, while centralized procurement, volume discounts, and falling sequencing costs may moderate revenue growth per screened individual.

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The segmentation of the global NGS kits market by workflow, application, sequencing type, end user, and region helps organizations identify where preparation, enrichment, cluster-generation, DNA-sequencing, and RNA-sequencing portfolios can address unmet workflow needs. It supports decisions on sample compatibility, multiplexing, automation, assay content, and platform alignment.

Growth/Marketing Strategy: Expanding genomics adoption, rising clinical applications, long-read growth, strategic partnerships, and geographic expansion are shaping commercialization. The report helps organizations prioritize customer groups, use cases, channels, collaborations, and regional markets where recurring kit consumption and workflow conversion can support growth.

Competitive Strategy: Competition is influenced by portfolio breadth, platform compatibility, chemistry performance, automation, regulatory readiness, distribution, supply reliability, and recent developments. Comparing these factors helps organizations assess differentiated positioning, partnership opportunities, portfolio gaps, and the capabilities required to compete across research and clinical workflows.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Years from 2024 to 2036 have been considered for market estimation; 2025 is the base year, and 2026-2036 is the forecast period.
  • The intended ecosystem inputs include NGS kit companies, platform providers, distributors, academic and research institutions, pharmaceutical and biotechnology companies, and clinical and diagnostic laboratories.
  • Public-company financial information has been sourced from annual reports and investor materials; private-company estimates have been developed from disclosed funding, partnerships, operating indicators, and validated research inputs rather than treated as reported revenue.
  • The market has been mapped through commercially available in-scope library-preparation, target-enrichment, cluster-generation, and sequencing kits, followed by identification of companies with relevant portfolios and market activity.

Primary Research

The intended primary-research approach covers NGS kit suppliers, sequencing-platform providers, distributors, core facilities, academic laboratories, pharmaceutical and biotechnology companies, and clinical and diagnostic laboratories. Relevant respondents include executives, product and portfolio leaders, business-development and commercial heads, research and development scientists, laboratory directors, procurement leaders, quality and regulatory professionals, and sequencing-core managers. Primary interviews are proposed for validation; this RD does not represent that interviews have already been completed.

The key data points intended from primary sources include:

  • validation and triangulation of market numbers and graphs
  • validation of report segmentation and qualitative findings
  • understanding the competitive landscape and business models
  • current and proposed kit production, sales, and sequencing-consumable demand
  • validation of estimates for the different market segments
  • percentage splits for regional analysis

Secondary Research

Open Sources

  • Recognized publications, articles from established authors, white papers, directories, and major databases
  • Annual reports, regulatory filings, and investor presentations of leading market participants
  • Company websites and detailed reviews of product portfolios and workflow documentation
  • Peer-reviewed journals, technical white papers, official press releases, and reputable news sources
  • Paid databases

The key data points taken from secondary sources include:

  • market segmentation and percentage-share inputs
  • market value inputs
  • key industry and portfolio trends among leading players
  • qualitative insights into technology developments, workflow trends, and emerging innovation
  • quantitative inputs used for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The global next-generation sequencing (NGS) kits market encompasses established sequencing-platform providers, diversified life science companies, and specialized library preparation and target enrichment suppliers. Illumina, Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies plc, Pacific Biosciences of California, Inc., and MGI Tech Co., Ltd. compete primarily through sequencing ecosystems, proprietary chemistries, platform-specific consumables, and recurring reagent sales. Agilent Technologies, Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Danaher Corporation, Bio-Rad Laboratories, Inc., Takara Bio Inc., New England Biolabs, Inc., and Promega Corporation maintain strong positions across library preparation, target enrichment, sample processing, amplification, and application-specific workflows.

Competition is increasingly shaped by improvements in sequencing accuracy, throughput, turnaround time, automation compatibility, and sample-input requirements. Market participants are also expanding their portfolios through oncology panels, rare disease solutions, infectious disease assays, long-read workflows, and RNA sequencing applications. Strategic partnerships, product launches, regulatory approvals, distribution expansion, and acquisitions remain important competitive approaches.

Specialized companies, including Twist Bioscience Corporation, seqWell, Inc., and Creative Biogene, compete through differentiated enrichment technologies, multiplexing solutions, custom assay development, and flexible workflow offerings. The market remains innovation-intensive, with customer purchasing decisions influenced by platform compatibility, workflow simplicity, data quality, cost per sample, technical support, and supply reliability. Overall, competition is expected to intensify as vendors pursue broader clinical adoption, geographic expansion, and recurring consumables revenue.

Some prominent names established in this market are:

  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • QIAGEN N.V.
  • Takara Bio Inc.
  • Oxford Nanopore Technologies plc
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Pacific Biosciences of California, Inc.
  • MGI Tech Co., Ltd.
  • New England Biolabs, Inc.
  • Twist Bioscience Corporation
  • seqWell, Inc.
  • Promega Corporation
  • Creative Biogene

Table of Contents

Executive Summary

Scope and Definition

1 Global NGS Kits Market: Industry Outlook

  • 1.1 Market Overview and Ecosystem
    • 1.1.1 Introduction
    • 1.1.2 Evolution of NGS Technology
    • 1.1.3 Workflow of NGS Kits
    • 1.1.4 Patent Analysis
      • 1.1.4.1 Patent Filing Trend by Region
      • 1.1.4.2 Patent Filing Trend by Country
      • 1.1.4.3 Patent Filing Trend (by Year)
    • 1.1.5 Supply Chain Analysis
    • 1.1.6 Trends: Current and Future Impact Assessment
      • 1.1.6.1 Impact Analysis
        • 1.1.6.1.1 Shift toward Higher-Throughput, Automated, Miniaturized, and Flexible Sequencing Workflows
        • 1.1.6.1.2 Growing Long-Read Share and Increasing Use of Multi-Platform Sequencing Portfolios
        • 1.1.6.1.3 Shift toward Broader Combined DNA/RNA and Liquid-Biopsy-Compatible Assay Designs
    • 1.1.7 Regulatory Landscape
      • 1.1.7.1 North America
        • 1.1.7.1.1 U.S.
        • 1.1.7.1.2 Canada
      • 1.1.7.2 Europe
        • 1.1.7.2.1 European Union
        • 1.1.7.2.2 U.K.
      • 1.1.7.3 Asia-Pacific
        • 1.1.7.3.1 Japan
        • 1.1.7.3.2 China
        • 1.1.7.3.3 India
        • 1.1.7.3.4 Rest-of-Asia-Pacific
      • 1.1.7.4 Latin America
        • 1.1.7.4.1 Brazil
        • 1.1.7.4.2 Mexico
      • 1.1.7.5 Rest-of-the-World
  • 1.2 Market Dynamics
    • 1.2.1 Market Drivers
      • 1.2.1.1 Routine Clinical NGS Integration across Established Diagnostic Pathways Expands Recurring Kit Consumption
      • 1.2.1.2 Active Public Genomics and Pathogen-Surveillance Programs Sustain Programmatic Consumables Procurement
      • 1.2.1.3 Biomarker-Driven Drug Development and NGS Companion-Diagnostic Co-Development Generate Pharmaceutical and Central-Laboratory Kit Demand
    • 1.2.2 Market Restraints
      • 1.2.2.1 Fragmented Reimbursement, Regulatory, and Validation Requirements Delay Clinical Adoption and Market Access
      • 1.2.2.2 High End-to-End Implementation Burden and Limited Laboratory Capacity Constrain Sequencing Utilization
      • 1.2.2.3 Trade Restrictions and Platform-Specific Supply Dependencies Limit Regional Consumables Access
    • 1.2.3 Market Opportunities
      • 1.2.3.1 Scaling Genome-First Newborn and Population Screening from Pilots into Routine Care
      • 1.2.3.2 Decentralized Clinical NGS Expansion across Underpenetrated Countries and Regional Laboratories
      • 1.2.3.3 Clinical Adoption of Long-Read Sequencing for Unresolved and Complex Disease Workflows

2 Global NGS Kits Market (by Workflow), $Million, 2024-2036

  • 2.1 Library Preparation
    • 2.1.1 Overview
    • 2.1.2 Market Sizing and Forecast
    • 2.1.3 Library Preparation Kits
      • 2.1.3.1 Market Sizing and Forecast
    • 2.1.4 Target Enrichment Kits
      • 2.1.4.1 Market Sizing and Forecast
  • 2.2 Cluster Generation
    • 2.2.1 Overview
    • 2.2.2 Market Sizing and Forecast
  • 2.3 Sequencing Reagents/Kits
    • 2.3.1 Overview
    • 2.3.2 Market Sizing and Forecast
    • 2.3.3 DNA Sequencing Kits
      • 2.3.3.1 Market Sizing and Forecast
    • 2.3.4 RNA Sequencing Kits
      • 2.3.4.1 Market Sizing and Forecast

3 Global NGS Kits Market (by Sequencing Type), $Million, 2024-2036

  • 3.1 WES and WGS
    • 3.1.1 Overview
    • 3.1.2 Market Sizing and Forecast
  • 3.2 Targeted Sequencing
    • 3.2.1 Overview
    • 3.2.2 Market Sizing and Forecast
  • 3.3 Long-Read Sequencing
    • 3.3.1 Overview
    • 3.3.2 Market Sizing and Forecast
  • 3.4 Other Sequencing
    • 3.4.1 Overview
    • 3.4.2 Market Sizing and Forecast

4 Global NGS Kits Market (by Application), $Million, 2024-2036

  • 4.1 Oncology
    • 4.1.1 Overview
    • 4.1.2 Market Sizing and Forecast
    • 4.1.3 Solid Tumors
      • 4.1.3.1 Market Sizing and Forecast
    • 4.1.4 Hematological Malignancies
      • 4.1.4.1 Market Sizing and Forecast
  • 4.2 Rare Diseases
    • 4.2.1 Overview
    • 4.2.2 Market Sizing and Forecast
  • 4.3 Genetic Disorders
    • 4.3.1 Overview
    • 4.3.2 Market Sizing and Forecast
  • 4.4 Reproductive Health
    • 4.4.1 Overview
    • 4.4.2 Market Sizing and Forecast
  • 4.5 Infectious Diseases
    • 4.5.1 Overview
    • 4.5.2 Market Sizing and Forecast
    • 4.5.3 Viral Infections
      • 4.5.3.1 Market Sizing and Forecast
    • 4.5.4 Bacterial Infections
      • 4.5.4.1 Market Sizing and Forecast
    • 4.5.5 Fungal and Parasitic Infections
      • 4.5.5.1 Market Sizing and Forecast
  • 4.6 Others
    • 4.6.1 Overview
    • 4.6.2 Market Sizing and Forecast

5 Global NGS Kits Market (by End User), $Million, 2024-2036

  • 5.1 Academic and Research Institutes
    • 5.1.1 Overview
    • 5.1.2 Market Sizing and Forecast
  • 5.2 Pharmaceutical and Biotechnology Companies
    • 5.2.1 Overview
    • 5.2.2 Market Sizing and Forecast
  • 5.3 Clinical and Diagnostic Laboratories
    • 5.3.1 Overview
    • 5.3.2 Market Sizing and Forecast
  • 5.4 Other End Users
    • 5.4.1 Overview
    • 5.4.2 Market Sizing and Forecast

6 Global NGS Kits Market (by Region), $Million, 2024-2036

  • 6.1 Regional Summary
  • 6.2 North America
    • 6.2.1 Regional Overview
    • 6.2.2 Driving Factors for Market Growth
    • 6.2.3 Factors Challenging the Market
    • 6.2.4 Analyst View
    • 6.2.5 Market Sizing and Forecast
      • 6.2.5.1 North America NGS Kits Market, by Application
      • 6.2.5.2 North America NGS Kits Market, by End User
      • 6.2.5.3 North America NGS Kits Market, by Country
        • 6.2.5.3.1 U.S.
          • 6.2.5.3.1.1 Country Overview
          • 6.2.5.3.1.2 Driving Factors for Market Growth
          • 6.2.5.3.1.3 Factors Challenging the Market
          • 6.2.5.3.1.4 Analyst View
          • 6.2.5.3.1.5 Market Sizing and Forecast
          • 6.2.5.3.1.5.1 U.S. NGS Kits Market, by Application
          • 6.2.5.3.1.5.2 U.S. NGS Kits Market, by End User
        • 6.2.5.3.2 Canada
          • 6.2.5.3.2.1 Country Overview
          • 6.2.5.3.2.2 Driving Factors for Market Growth
          • 6.2.5.3.2.3 Factors Challenging the Market
          • 6.2.5.3.2.4 Analyst View
          • 6.2.5.3.2.5 Market Sizing and Forecast
          • 6.2.5.3.2.5.1 Canada NGS Kits Market, by Application
          • 6.2.5.3.2.5.2 Canada NGS Kits Market, by End User
  • 6.3 Europe
    • 6.3.1 Regional Overview
    • 6.3.2 Driving Factors for Market Growth
    • 6.3.3 Factors Challenging the Market
    • 6.3.4 Analyst View
    • 6.3.5 Market Sizing and Forecast
      • 6.3.5.1 Europe NGS Kits Market, by Application
      • 6.3.5.2 Europe NGS Kits Market, by End User
      • 6.3.5.3 Europe NGS Kits Market, by Country
        • 6.3.5.3.1 Germany
          • 6.3.5.3.1.1 Country Overview
          • 6.3.5.3.1.2 Driving Factors for Market Growth
          • 6.3.5.3.1.3 Factors Challenging the Market
          • 6.3.5.3.1.4 Analyst View
          • 6.3.5.3.1.5 Market Sizing and Forecast
          • 6.3.5.3.1.5.1 Germany NGS Kits Market, by Application
          • 6.3.5.3.1.5.2 Germany NGS Kits Market, by End User
        • 6.3.5.3.2 France
          • 6.3.5.3.2.1 Country Overview
          • 6.3.5.3.2.2 Driving Factors for Market Growth
          • 6.3.5.3.2.3 Factors Challenging the Market
          • 6.3.5.3.2.4 Analyst View
          • 6.3.5.3.2.5 Market Sizing and Forecast
          • 6.3.5.3.2.5.1 France NGS Kits Market, by Application
          • 6.3.5.3.2.5.2 France NGS Kits Market, by End User
        • 6.3.5.3.3 U.K.
          • 6.3.5.3.3.1 Country Overview
          • 6.3.5.3.3.2 Driving Factors for Market Growth
          • 6.3.5.3.3.3 Factors Challenging the Market
          • 6.3.5.3.3.4 Analyst View
          • 6.3.5.3.3.5 Market Sizing and Forecast
          • 6.3.5.3.3.5.1 U.K. NGS Kits Market, by Application
          • 6.3.5.3.3.5.2 U.K. NGS Kits Market, by End User
        • 6.3.5.3.4 Italy
          • 6.3.5.3.4.1 Country Overview
          • 6.3.5.3.4.2 Driving Factors for Market Growth
          • 6.3.5.3.4.3 Factors Challenging the Market
          • 6.3.5.3.4.4 Analyst View
          • 6.3.5.3.4.5 Market Sizing and Forecast
          • 6.3.5.3.4.5.1 Italy NGS Kits Market, by Application
          • 6.3.5.3.4.5.2 Italy NGS Kits Market, by End User
        • 6.3.5.3.5 Spain
          • 6.3.5.3.5.1 Country Overview
          • 6.3.5.3.5.2 Driving Factors for Market Growth
          • 6.3.5.3.5.3 Factors Challenging the Market
          • 6.3.5.3.5.4 Analyst View
          • 6.3.5.3.5.5 Market Sizing and Forecast
          • 6.3.5.3.5.5.1 Spain NGS Kits Market, by Application
          • 6.3.5.3.5.5.2 Spain NGS Kits Market, by End User
        • 6.3.5.3.6 Rest-of-Europe
          • 6.3.5.3.6.1 Country Overview
          • 6.3.5.3.6.2 Driving Factors for Market Growth
          • 6.3.5.3.6.3 Factors Challenging the Market
          • 6.3.5.3.6.4 Analyst View
          • 6.3.5.3.6.5 Market Sizing and Forecast
          • 6.3.5.3.6.5.1 Rest-of-Europe NGS Kits Market, by Application
          • 6.3.5.3.6.5.2 Rest-of-Europe NGS Kits Market, by End User
  • 6.4 Asia-Pacific
    • 6.4.1 Regional Overview
    • 6.4.2 Driving Factors for Market Growth
    • 6.4.3 Factors Challenging the Market
    • 6.4.4 Analyst View
    • 6.4.5 Market Sizing and Forecast
      • 6.4.5.1 Asia-Pacific NGS Kits Market, by Application
      • 6.4.5.2 Asia-Pacific NGS Kits Market, by End User
      • 6.4.5.3 Asia-Pacific NGS Kits Market, by Country
        • 6.4.5.3.1 China
          • 6.4.5.3.1.1 Country Overview
          • 6.4.5.3.1.2 Driving Factors for Market Growth
          • 6.4.5.3.1.3 Factors Challenging the Market
          • 6.4.5.3.1.4 Analyst View
          • 6.4.5.3.1.5 Market Sizing and Forecast
          • 6.4.5.3.1.5.1 China NGS Kits Market, by Application
          • 6.4.5.3.1.5.2 China NGS Kits Market, by End User
        • 6.4.5.3.2 Japan
          • 6.4.5.3.2.1 Country Overview
          • 6.4.5.3.2.2 Driving Factors for Market Growth
          • 6.4.5.3.2.3 Factors Challenging the Market
          • 6.4.5.3.2.4 Analyst View
          • 6.4.5.3.2.5 Market Sizing and Forecast
          • 6.4.5.3.2.5.1 Japan NGS Kits Market, by Application
          • 6.4.5.3.2.5.2 Japan NGS Kits Market, by End User
        • 6.4.5.3.3 India
          • 6.4.5.3.3.1 Country Overview
          • 6.4.5.3.3.2 Driving Factors for Market Growth
          • 6.4.5.3.3.3 Factors Challenging the Market
          • 6.4.5.3.3.4 Analyst View
          • 6.4.5.3.3.5 Market Sizing and Forecast
          • 6.4.5.3.3.5.1 India NGS Kits Market, by Application
          • 6.4.5.3.3.5.2 India NGS Kits Market, by End User
        • 6.4.5.3.4 Australia
          • 6.4.5.3.4.1 Country Overview
          • 6.4.5.3.4.2 Driving Factors for Market Growth
          • 6.4.5.3.4.3 Factors Challenging the Market
          • 6.4.5.3.4.4 Analyst View
          • 6.4.5.3.4.5 Market Sizing and Forecast
          • 6.4.5.3.4.5.1 Australia NGS Kits Market, by Application
          • 6.4.5.3.4.5.2 Australia NGS Kits Market, by End User
        • 6.4.5.3.5 South Korea
          • 6.4.5.3.5.1 Country Overview
          • 6.4.5.3.5.2 Driving Factors for Market Growth
          • 6.4.5.3.5.3 Factors Challenging the Market
          • 6.4.5.3.5.4 Analyst View
          • 6.4.5.3.5.5 Market Sizing and Forecast
          • 6.4.5.3.5.5.1 South Korea NGS Kits Market, by Application
          • 6.4.5.3.5.5.2 South Korea NGS Kits Market, by End User
        • 6.4.5.3.6 Rest-of-Asia-Pacific
          • 6.4.5.3.6.1 Country Overview
          • 6.4.5.3.6.2 Driving Factors for Market Growth
          • 6.4.5.3.6.3 Factors Challenging the Market
          • 6.4.5.3.6.4 Analyst View
          • 6.4.5.3.6.5 Market Sizing and Forecast
          • 6.4.5.3.6.5.1 Rest-of-Asia-Pacific NGS Kits Market, by Application
          • 6.4.5.3.6.5.2 Rest-of-Asia-Pacific NGS Kits Market, by End User
  • 6.5 Latin America
    • 6.5.1 Regional Overview
    • 6.5.2 Driving Factors for Market Growth
    • 6.5.3 Factors Challenging the Market
    • 6.5.4 Analyst View
    • 6.5.5 Market Sizing and Forecast
      • 6.5.5.1 Latin America NGS Kits Market, by Application
      • 6.5.5.2 Latin America NGS Kits Market, by End User
      • 6.5.5.3 Latin America NGS Kits Market, by Country
        • 6.5.5.3.1 Brazil
          • 6.5.5.3.1.1 Country Overview
          • 6.5.5.3.1.2 Driving Factors for Market Growth
          • 6.5.5.3.1.3 Factors Challenging the Market
          • 6.5.5.3.1.4 Analyst View
          • 6.5.5.3.1.5 Market Sizing and Forecast
          • 6.5.5.3.1.5.1 Brazil NGS Kits Market, by Application
          • 6.5.5.3.1.5.2 Brazil NGS Kits Market, by End User
        • 6.5.5.3.2 Mexico
          • 6.5.5.3.2.1 Country Overview
          • 6.5.5.3.2.2 Driving Factors for Market Growth
          • 6.5.5.3.2.3 Factors Challenging the Market
          • 6.5.5.3.2.4 Analyst View
          • 6.5.5.3.2.5 Market Sizing and Forecast
          • 6.5.5.3.2.5.1 Mexico NGS Kits Market, by Application
          • 6.5.5.3.2.5.2 Mexico NGS Kits Market, by End User
        • 6.5.5.3.3 Rest-of-Latin America
          • 6.5.5.3.3.1 Country Overview
          • 6.5.5.3.3.2 Driving Factors for Market Growth
          • 6.5.5.3.3.3 Factors Challenging the Market
          • 6.5.5.3.3.4 Analyst View
          • 6.5.5.3.3.5 Market Sizing and Forecast
          • 6.5.5.3.3.5.1 Rest-of-Latin America NGS Kits Market, by Application
          • 6.5.5.3.3.5.2 Rest-of-Latin-America NGS Kits Market, by End User
  • 6.6 Rest-of-the-World
    • 6.6.1 Regional Overview
    • 6.6.2 Driving Factors for Market Growth
    • 6.6.3 Factors Challenging the Market
    • 6.6.4 Analyst View
    • 6.6.5 Market Sizing and Forecast
      • 6.6.5.1 Rest-of-the-World NGS Kits Market, by Application
      • 6.6.5.2 Rest-of-the-World NGS Kits Market, by End User

7 Competitive Benchmarking and Company Profiles

  • 7.1 Key Strategies and Developments
    • 7.1.1 New Offerings
    • 7.1.2 Mergers and Acquisitions
    • 7.1.3 Partnership, Alliances, and Business Expansion
  • 7.2 Company Profiles
    • 7.2.1 Bio-Rad Laboratories, Inc.
      • 7.2.1.1 Overview
      • 7.2.1.2 Top Products/Product Portfolio
      • 7.2.1.3 Target Customers/End-User
      • 7.2.1.4 Key Personnel
      • 7.2.1.5 Analyst View
    • 7.2.2 MGI Tech Co., Ltd.
      • 7.2.2.1 Overview
      • 7.2.2.2 Top Products/Product Portfolio
      • 7.2.2.3 Target Customers/End-User
      • 7.2.2.4 Key Personnel
      • 7.2.2.5 Analyst View
    • 7.2.3 F. Hoffmann-La Roche Ltd.
      • 7.2.3.1 Overview
      • 7.2.3.2 Top Products/Product Portfolio
      • 7.2.3.3 Target Customers/End-User
      • 7.2.3.4 Key Personnel
      • 7.2.3.5 Analyst View
    • 7.2.4 Agilent Technologies, Inc.
      • 7.2.4.1 Overview
      • 7.2.4.2 Top Products/Product Portfolio
      • 7.2.4.3 Target Customers/End-User
      • 7.2.4.4 Key Personnel
      • 7.2.4.5 Analyst View
    • 7.2.5 QIAGEN N.V.
      • 7.2.5.1 Overview
      • 7.2.5.2 Top Products/Product Portfolio
      • 7.2.5.3 Target Customers/End-User
      • 7.2.5.4 Key Personnel
      • 7.2.5.5 Analyst View
    • 7.2.6 Thermo Fisher Scientific Inc.
      • 7.2.6.1 Overview
      • 7.2.6.2 Top Products/Product Portfolio
      • 7.2.6.3 Target Customers/End-User
      • 7.2.6.4 Key Personnel
      • 7.2.6.5 Analyst View
    • 7.2.7 Danaher Corporation
      • 7.2.7.1 Overview
      • 7.2.7.2 Top Products/Product Portfolio
      • 7.2.7.3 Target Customers/End-User
      • 7.2.7.4 Key Personnel
      • 7.2.7.5 Analyst View
    • 7.2.8 Illumina, Inc.
      • 7.2.8.1 Overview
      • 7.2.8.2 Top Products/Product Portfolio
      • 7.2.8.3 Target Customers/End-User
      • 7.2.8.4 Key Personnel
      • 7.2.8.5 Analyst View
    • 7.2.9 New England Biolabs, Inc.
      • 7.2.9.1 Overview
      • 7.2.9.2 Top Products/Product Portfolio
      • 7.2.9.3 Target Customers/End-User
      • 7.2.9.4 Key Personnel
      • 7.2.9.5 Analyst View
    • 7.2.10 Oxford Nanopore Technologies plc
      • 7.2.10.1 Overview
      • 7.2.10.2 Top Products/Product Portfolio
      • 7.2.10.3 Target Customers/End-User
      • 7.2.10.4 Key Personnel
      • 7.2.10.5 Analyst View
    • 7.2.11 Pacific Biosciences of California, Inc.
      • 7.2.11.1 Overview
      • 7.2.11.2 Top Products/Product Portfolio
      • 7.2.11.3 Target Customers/End-User
      • 7.2.11.4 Key Personnel
      • 7.2.11.5 Analyst View
    • 7.2.12 Revvity, Inc.
      • 7.2.12.1 Overview
      • 7.2.12.2 Top Products/Product Portfolio
      • 7.2.12.3 Target Customers/End-User
      • 7.2.12.4 Key Personnel
      • 7.2.12.5 Analyst View
    • 7.2.13 Twist Bioscience Corporation
      • 7.2.13.1 Overview
      • 7.2.13.2 Top Products/Product Portfolio
      • 7.2.13.3 Target Customers/End-User
      • 7.2.13.4 Key Personnel
      • 7.2.13.5 Analyst View
    • 7.2.14 seqWell, Inc.
      • 7.2.14.1 Overview
      • 7.2.14.2 Top Products/Product Portfolio
      • 7.2.14.3 Target Customers/End-User
      • 7.2.14.4 Key Personnel
      • 7.2.14.5 Analyst View
    • 7.2.15 Takara Bio Inc.
      • 7.2.15.1 Overview
      • 7.2.15.2 Top Products/Product Portfolio
      • 7.2.15.3 Target Customers/End-User
      • 7.2.15.4 Key Personnel
      • 7.2.15.5 Analyst View

8 Research Methodology

  • 8.1 Data Sources
    • 8.1.1 Primary Data Sources
    • 8.1.2 Secondary Data Sources
    • 8.1.3 Data Triangulation
  • 8.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global NGS Kits Market (by Scenario), $Million, 2026, 2031, and 2036
  • Figure 2: Global NGS Kits Market (by Region), $Million, 2025, 2031, 2036
  • Figure 3: Global NGS Kits Market (by Workflow), $Million, 2025, 2031, and 2036
  • Figure 4: Global NGS Kits Market (by Application), $Million, 2025, 2031, and 2036
  • Figure 5: Global NGS Kits Market (by End User), $Million, 2025, 2031, and 2036
  • Figure 6: Evolution of Sequencing Technologies and NGS Consumables
  • Figure 7: NGS Kits Workflow
  • Figure 8: Global NGS Kits Market (by Region), January 2023-July 2026
  • Figure 9: Global NGS Kits Market (by Country), January 2023-July 2026
  • Figure 10: Global NGS Kits Market (by Year), January 2023-July 2026
  • Figure 11: Supply Chain and Risks within the Supply Chain
  • Figure 12: Global NGS Kits Market (by Workflow), $Million, 2025, 2031, and 2036
  • Figure 13: Global NGS Kits Market (Library Preparation), $Million, 2024-2036
  • Figure 14: Global NGS Kits Market (Library Preparation Kits), $Million, 2024-2036
  • Figure 15: Global NGS Kits Market (Target Enrichment Kits), $Million, 2024-2036
  • Figure 16: Global NGS Kits Market (Cluster Generation), $Million, 2024-2036
  • Figure 17: Global NGS Kits Market (Sequencing Reagents/Kits), $Million, 2024-2036
  • Figure 18: Global NGS Kits Market (DNA Sequencing Kits), $Million, 2024-2036
  • Figure 19: Global NGS Kits Market (RNA Sequencing Kits), $Million, 2024-2036
  • Figure 20: Global NGS Kits Market (by Sequencing Type), $Million, 2025, 2031, and 2036
  • Figure 21: Global NGS Kits Market (WES and WGS), $Million, 2024-2036
  • Figure 22: Global NGS Kits Market (Targeted Sequencing), $Million, 2024-2036
  • Figure 23: Global NGS Kits Market (Long-Read Sequencing), $Million, 2024-2036
  • Figure 24: Global NGS Kits Market (Other Sequencing), $Million, 2024-2036
  • Figure 25: Global NGS Kits Market (by Application), $Million, 2025, 2031, and 2036
  • Figure 26: Global NGS Kits Market (Oncology), $Million, 2024-2036
  • Figure 27: Global NGS Kits Market (Solid Tumors), $Million, 2024-2036
  • Figure 28: Global NGS Kits Market (Hematological Malignancies), $Million, 2024-2036
  • Figure 29: Global NGS Kits Market (Rare Diseases), $Million, 2024-2036
  • Figure 30: Global NGS Kits Market (Genetic Disorders), $Million, 2024-2036
  • Figure 31: Global NGS Kits Market (Reproductive Health), $Million, 2024-2036
  • Figure 32: Global NGS Kits Market (Infectious Diseases), $Million, 2024-2036
  • Figure 33: Global NGS Kits Market (Viral Infections), $Million, 2024-2036
  • Figure 34: Global NGS Kits Market (Bacterial Infections), $Million, 2024-2036
  • Figure 35: Global NGS Kits Market (Fungal and Parasitic Infections), $Million, 2024-2036
  • Figure 36: Global NGS Kits Market (Others), $Million, 2024-2036
  • Figure 37: Global NGS Kits Market (by End User), $Million, 2025, 2031, and 2036
  • Figure 38: Global NGS Kits Market (Academic and Research Institutes), $Million, 2024-2036
  • Figure 39: Global NGS Kits Market (Pharmaceutical and Biotechnology Companies), $Million, 2024-2036
  • Figure 40: Global NGS Kits Market (Clinical and Diagnostic Laboratories), $Million, 2024-2036
  • Figure 41: Global NGS Kits Market (Other End Users), $Million, 2024-2036
  • Figure 42: North America NGS Kits Market, $Million, 2024-2036
  • Figure 43: U.S. NGS Kits Market, $Million, 2024-2036
  • Figure 44: Canada NGS Kits Market, $Million, 2024-2036
  • Figure 45: Europe NGS Kits Market, $Million, 2024-2036
  • Figure 46: Germany NGS Kits Market, $Million, 2024-2036
  • Figure 47: France NGS Kits Market, $Million, 2024-2036
  • Figure 48: U.K. NGS Kits Market, $Million, 2024-2036
  • Figure 49: Italy NGS Kits Market, $Million, 2024-2036
  • Figure 50: Spain NGS Kits Market, $Million, 2024-2036
  • Figure 51: Rest-of-Europe NGS Kits Market, $Million, 2024-2036
  • Figure 52: Asia-Pacific NGS Kits Market, $Million, 2024-2036
  • Figure 53: China NGS Kits Market, $Million, 2024-2036
  • Figure 54: Japan NGS Kits Market, $Million, 2024-2036
  • Figure 55: India NGS Kits Market, $Million, 2024-2036
  • Figure 56: Australia NGS Kits Market, $Million, 2024-2036
  • Figure 57: South Korea NGS Kits Market, $Million, 2024-2036
  • Figure 58: Rest-of-Asia-Pacific NGS Kits Market, $Million, 2024-2036
  • Figure 59: Latin America NGS Kits Market, $Million, 2024-2036
  • Figure 60: Brazil NGS Kits Market, $Million, 2024-2036
  • Figure 61: Mexico NGS Kits Market, $Million, 2024-2036
  • Figure 62: Rest-of-Latin America NGS Kits Market, $Million, 2024-2036
  • Figure 63: Rest-of-the-World NGS Kits Market, $Million, 2024-2036
  • Figure 64: Data Triangulation
  • Figure 65: Top-Down and Bottom-Up Approach
  • Figure 66: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
  • Table 3: Global NGS Kits Market (by Region), $Million, 2024-2036
  • Table 4: North America NGS Kits Market (by Application), $Million, 2024-2036
  • Table 5: North America NGS Kits Market (by End User), $Million, 2024-2036
  • Table 6: North America NGS Kits Market (by Country), $Million, 2024-2036
  • Table 7: U.S. NGS Kits Market (by Application), $Million, 2024-2036
  • Table 8: U.S. NGS Kits Market (by End User), $Million, 2024-2036
  • Table 9: Canada NGS Kits Market (by Application), $Million, 2024-2036
  • Table 10: Canada NGS Kits Market (by End User), $Million, 2024-2036
  • Table 11: Europe NGS Kits Market (by Application), $Million, 2024-2036
  • Table 12: Europe NGS Kits Market (by End User), $Million, 2024-2036
  • Table 13: Europe NGS Kits Market (by Country), $Million, 2024-2036
  • Table 14: Germany NGS Kits Market (by Application), $Million, 2024-2036
  • Table 15: Germany NGS Kits Market (by End User), $Million, 2024-2036
  • Table 16: France NGS Kits Market (by Application), $Million, 2024-2036
  • Table 17: France NGS Kits Market (by End User), $Million, 2024-2036
  • Table 18: U.K. NGS Kits Market (by Application), $Million, 2024-2036
  • Table 19: U.K. NGS Kits Market (by End User), $Million, 2024-2036
  • Table 20: Italy NGS Kits Market (by Application), $Million, 2024-2036
  • Table 21: Italy NGS Kits Market (by End User), $Million, 2024-2036
  • Table 22: Spain NGS Kits Market (by Application), $Million, 2024-2036
  • Table 23: Spain NGS Kits Market (by End User), $Million, 2024-2036
  • Table 24: Rest-of-Europe NGS Kits Market (by Application), $Million, 2024-2036
  • Table 25: Rest-of-Europe NGS Kits Market (by End User), $Million, 2024-2036
  • Table 26: Asia-Pacific NGS Kits Market (by Application), $Million, 2024-2036
  • Table 27: Asia-Pacific NGS Kits Market (by End User), $Million, 2024-2036
  • Table 28: Asia-Pacific NGS Kits Market (by Country), $Million, 2024-2036
  • Table 29: China NGS Kits Market (by Application), $Million, 2024-2036
  • Table 30: China NGS Kits Market (by End User), $Million, 2024-2036
  • Table 31: Japan NGS Kits Market (by Application), $Million, 2024-2036
  • Table 32: Japan NGS Kits Market (by End User), $Million, 2024-2036
  • Table 33: India NGS Kits Market (by Application), $Million, 2024-2036
  • Table 34: India NGS Kits Market (by End User), $Million, 2024-2036
  • Table 35: Australia NGS Kits Market (by Application), $Million, 2024-2036
  • Table 36: Australia NGS Kits Market (by End User), $Million, 2024-2036
  • Table 37: South Korea NGS Kits Market (by Application), $Million, 2024-2036
  • Table 38: South Korea NGS Kits Market (by End User), $Million, 2024-2036
  • Table 39: Rest-of-Asia-Pacific NGS Kits Market (by Application), $Million, 2024-2036
  • Table 40: Rest-of-Asia-Pacific NGS Kits Market (by End User), $Million, 2024-2036
  • Table 41: Latin America NGS Kits Market (by Application), $Million, 2024-2036
  • Table 42: Latin America NGS Kits Market (by End User), $Million, 2024-2036
  • Table 43: Latin America NGS Kits Market (by Country), $Million, 2024-2036
  • Table 44: Brazil NGS Kits Market (by Application), $Million, 2024-2036
  • Table 45: Brazil NGS Kits Market (by End User), $Million, 2024-2036
  • Table 46: Mexico NGS Kits Market (by Application), $Million, 2024-2036
  • Table 47: Mexico NGS Kits Market (by End User), $Million, 2024-2036
  • Table 48: Rest-of-Latin-America NGS Kits Market (by Application), $Million, 2024-2036
  • Table 49: Rest-of-Latin-America NGS Kits Market (by End User), $Million, 2024-2036
  • Table 50: Rest-of-the-World NGS Kits Market (by Application), $Million, 2024-2036
  • Table 51: Rest-of-the-World NGS Kits Market (by End User), $Million, 2024-2036
  • Table 52: Some of the Major Key Strategies: New Offerings, March-June 2026
  • Table 53: Some of the Major Key Strategies: Mergers and Acquisitions, July 2024-November 2025
  • Table 54: Some of the Major Key Strategies: Partnership, Alliances, and Business Expansion, November 2025-June 2026